Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

494
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
494
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

455
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
455
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

545
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
545
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

573
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
573
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

611
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
611
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

480
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
480

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Lateral Epicondylitis: A Prospective Comparative Study Comparing the Local Infiltrations of Leucocyte Enriched Platelet-Rich Plasma (L-aPRP), Glucocorticoid and Normal Saline.

Malaysian orthopaedic journal·2022
Same author

Clinical pathologic findings of Propionibacterium acnes endophthalmitis.

Ocular immunology and inflammation·2012
Same author

Local penicillin therapy for tropical ulcer.

United States naval medical bulletin·2010
Same author

An outbreak of avian malaria in captive yellowheads/mohua (Mohoua ochrocephala).

New Zealand veterinary journal·2008
Same author

Field investigation of advanced filtration for phosphorus removal from constructed treatment wetland effluents.

Environmental technology·2006
Same author

On first laboratory animal medicine training program.

Contemporary topics in laboratory animal science·2001

Related Experiment Video

Updated: Feb 5, 2026

Author Spotlight: Understanding the Effect of Herbal-Cake-Separated Moxibustion in Rats with Renal Faliure
06:46

Author Spotlight: Understanding the Effect of Herbal-Cake-Separated Moxibustion in Rats with Renal Faliure

Published on: December 22, 2023

1.2K

Calcific cardiomyopathy in advanced renal failure.

K K Arora, J P Lacy, R A Schacht

    Archives of Internal Medicine
    |April 1, 1975
    PubMed
    Summary

    High calcium-phosphorus levels in uremic patients undergoing hemodialysis can lead to fatal heart complications. This study highlights the critical role of oral phosphate binders in preventing metastatic calcification.

    Area of Science:

    • Nephrology
    • Cardiology
    • Pathology

    Background:

    • Uremic patients on maintenance hemodialysis often face complications related to mineral and bone disorders.
    • Elevated calcium-phosphate product is a known risk factor for calcification in chronic kidney disease.

    Purpose of the Study:

    • To investigate the link between high calcium-phosphorus product and fatal cardiac complications in hemodialysis patients.
    • To identify the role of metastatic myocardial calcification in intractable heart failure and atrioventricular block.

    Main Methods:

    • Case study analysis of four uremic patients on maintenance hemodialysis.
    • Review of clinical data including heart failure, atrioventricular block, and calcium-phosphorus product levels.
    • Autopsy findings to confirm metastatic myocardial calcification.

    More Related Videos

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
    10:08

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

    Published on: February 17, 2018

    14.0K
    Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
    08:43

    Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

    Published on: May 31, 2016

    20.3K

    Related Experiment Videos

    Last Updated: Feb 5, 2026

    Author Spotlight: Understanding the Effect of Herbal-Cake-Separated Moxibustion in Rats with Renal Faliure
    06:46

    Author Spotlight: Understanding the Effect of Herbal-Cake-Separated Moxibustion in Rats with Renal Faliure

    Published on: December 22, 2023

    1.2K
    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
    10:08

    Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

    Published on: February 17, 2018

    14.0K
    Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
    08:43

    Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation

    Published on: May 31, 2016

    20.3K

    Main Results:

    • All four patients presented with intractable heart failure and atrioventricular block.
    • Persistently high calcium-phosphorus products (over 60) were observed in all cases.
    • Autopsy confirmed metastatic myocardial calcification as a common pathological finding.

    Conclusions:

    • Inability to effectively manage phosphate levels with oral phosphate binders can lead to fatal metastatic myocardial calcification.
    • Maintaining a low calcium-phosphorus product is crucial for preventing severe cardiac complications in hemodialysis patients.
    • This highlights a critical treatment challenge and a potentially fatal complication in uremic patients.